PHIO

Phio Pharmaceuticals Corp

Add to Watchlist

Advanced Chart

2.140

-0.01(-0.465%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

2.140

Open

2.140

VWAP

2.14

Vol

9.27K

Mkt Cap

12.31M

Low

2.140

Amount

19.83K

EV/EBITDA(TTM)

Total Shares

4.59M

1.54M

EV/OCF(TTM)

P/S(TTM)

Phio Pharmaceuticals Corp. is a clinical-stage biotechnology company. The Company's INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. It is developing therapeutics that are designed to leverage INTASYL to target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. The Company's pipeline is focused on the treatment of cutaneous Squamous Cell Carcinoma (cSCC) and melanoma. Its product pipeline includes PH-762 and PH-894. PH-762 is an INTASYL compound designed to reduce the expression of cell death protein 1 (PD-1). PD-1 is a protein that inhibits T cells’ ability to kill cancer cells and is a clinically validated target in immunotherapy. PH-894 is an INTASYL compound that is designed to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, thereby affecting the immune system as well as the tumor.

1 Analyst Rating

Wall Street analysts forecast PHIO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PHIO is 14.00 USD with a low forecast of 14.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 2.140

Low

14.00

Averages

14.00

High

14.00

Current: 2.140

Low

14.00

Averages

14.00

High

14.00

H.C. Wainwright

initiated

$14

2025-06-05

Reason

H.C. Wainwright

Price Target

$14

2025-06-05

initiated

Reason

H.C. Wainwright assumed coverage of Phio Pharmaceuticals with a Buy rating and $14 price target. Phio's lead asset is PH-762 is an siRNA-based therapy formulated to safely inhibit PD-1 expression on T cells within the tumor microenvironment to drive anti-tumor activity, the analyst tells investors in a research note. The firm believes the company is "flying under the radar with investors" and has a bullish outlook for the stock.

HC Wainwright & Co.

Vernon Bernardino

Strong Buy

Reiterates

2025-04-08

Reason

HC Wainwright & Co.

Vernon Bernardino

Price Target

2025-04-08

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Vernon Bernardino

Strong Buy

Reiterates

2025-02-19

Reason

HC Wainwright & Co.

Vernon Bernardino

Price Target

2025-02-19

Reiterates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Phio Pharmaceuticals Corp (PHIO.O) is -1.59, compared to its 5-year average forward P/E of -2.30. For a more detailed relative valuation and DCF analysis to assess Phio Pharmaceuticals Corp 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-2.30

Current PE

-1.59

Overvalued PE

6.39

Undervalued PE

-10.99

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.01

Current EV/EBITDA

-0.17

Overvalued EV/EBITDA

0.06

Undervalued EV/EBITDA

-0.04

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.30

Current PS

0.00

Overvalued PS

0.88

Undervalued PS

-0.28